

Combination strategies for rational drug targeting of pancreatic ductal adenocarcinoma (PDAC)



PRINCIPLE INVESTIGATORS:
Hazal Köse, Prof. Dr. Ulrich Keller, PD Dr. Matthias Wirth
Charité



Pharma

Oncology

SUMMARY

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor prognosis. This adverse outcome can be in part attributed to the delayed diagnosis of PDAC, in most cases, combined with the unresponsiveness of a subset of patients to the current treatments.

Our aim is to develop a novel combination therapy for PDAC that does not only improve the treatment but also could provide a basis for immunotherapeutic interventions in PDAC and thus significantly improve patient's outcomes.

PROJECT GOALS

- Proof-of-concept of the combination strategy *in vivo*
- Characterization of the cellular ecosystem and immunomodulatory features upon therapeutic intervention using spatial transcriptomics
- Identification of new potential biomarkers in PDAC for therapy

LONG-TERM GOALS

- Clinical trials
- Licensing to industry or startup foundation